Silva Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
For the six months, sales was BDT 302.96 million compared to BDT 382.3 million a year ago. Net loss was BDT 16.22 million compared to net income of BDT 45.01 million a year ago. Basic loss per share from continuing operations was BDT 0.12 compared to basic earnings per share from continuing operations of BDT 0.33 a year ago.